Drug Profile
F 899
Alternative Names: F-899; rH GH dimerLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Generon (Shanghai) Corporation
- Developer Evive Biotech
- Class Growth hormones; Proteins
- Mechanism of Action Hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Growth disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Growth-disorders in China (Parenteral)
- 08 Sep 2020 Preclinical development is ongoing in China (Evive Biotech Pipeline, September 2020)
- 08 Sep 2020 F 899 is undergoing IND enabling studies for Growth disorders in China, prior to September 2020 (Evive Biotech Pipeline, September 2020)